Similarly, the treatment with anti-CTLA-4 mAb in a preclinical model of HNSCC that recapitulates the tobacco-related molecular profile showed complete response and no tumor recurrence accompanied by an increase of CD8+ T-cell infiltration and a reduction in Tregs cell proportion [68]. The gene discussed is CTLA4; the disease is neoplasm.